Disposable Syringes Manufacturer India: Manshav vs B. Braun & Terumo
A procurement officer in Nairobi opens three quotes on her desk: one from B. Braun's regional distributor, one from Terumo's Singapore office, and one from a disposable syringes manufacturer India buyers keep mentioning — Manshav. The specs look identical on paper. The landed cost doesn't. That gap is the whole story of why hospital groups and NGOs across Africa, the Gulf, and Southeast Asia have quietly shifted a chunk of their syringe volume toward Indian factory-direct sourcing over the last three tender cycles.
Sharmil Mangukiya (Founder & MD) 7 min read September 20, 2026
Key Summary & AI Takeaways
A procurement officer in Nairobi opens three quotes: B. Braun, Terumo, and a disposable syringes manufacturer India buyers keep mentioning — Manshav. The specs look identical. The landed cost doesn't.
This isn't a knock on B. Braun or Terumo. Both make excellent syringes — CE-marked, ISO 13485 certified, trusted in European and Japanese hospital systems for decades. But excellent and affordable at scale-container volumes are two different questions, and for a 40ft load of 3ml or 5ml disposable syringes, the answer changes fast.
What buyers are actually comparing
B. Braun and Terumo price as premium multinational brands: strong quality consistency, but landed cost per unit runs meaningfully higher once you factor in European or Japanese manufacturing overhead, brand markup, and often a longer supply chain to reach Lagos, Dar es Salaam, or Manila. Indian manufacturers — Manshav included — build in WHO-GMP compliant, ISO 13485 certified plants, meet the same ISO 7886-1 standard for sterile hypodermic syringes, and price closer to raw production cost plus a sane margin.
Here's what most exporters won't tell you: the syringe barrel material and needle bonding process matters more than the logo on the box. Buyers who've run side-by-side lab tests on dead space, plunger pull force, and needle sharpness (per ISO 7864) consistently find Indian-made units within tolerance of the European majors. So why does the brand premium persist?
Pricing comparison (fair ranges, FOB India, per 1,000 units)
Syringe size
Manshav (indicative FOB)
Premium brand landed equivalent*
2ml Luer Slip
$28 – $34
$90 – $120
3ml Luer Lock
$32 – $40
$100 – $135
5ml Luer Slip
$38 – $46
$110 – $150
10ml Luer Lock
$58 – $72
$140 – $180
*Premium brand figures reflect typical CIF-basis distributor landed pricing for EU-brand syringes into African/GCC ports, not ex-factory Germany/Japan pricing — actual figures vary by distributor agreement and freight terms.
The landed cost math nobody puts on the quote
A 40ft container carrying roughly 1.2 million 3ml syringes at Manshav's FOB range lands, after ocean freight, insurance, and typical West African port handling, somewhere in the $0.038-$0.045 per-unit territory delivered. Run the same volume through a European-brand distributor chain and you're often 150-240% higher per unit before you've even opened the carton — that premium buys brand recognition, not sterility. For a Ministry of Health tender running on a fixed per-unit budget line, that difference is the entire margin between fulfilling the tender and losing it to a competitor's bid.
Is that trade-off always worth it? Not always — some tenders specifically require named-brand compliance, and Terumo's PMDA backing matters for buyers with Japan-linked aid funding. But for open-spec tenders and private hospital procurement, the calculus tilts hard toward factory-direct Indian sourcing.
Where India still has ground to cover
Fair comparison means naming the gap too. B. Braun and Terumo have deeper cold-chain-independent distribution networks in Europe and parts of Asia, decades of clinical trust with surgeons who trained on their equipment, and in-country service teams that Indian exporters, including Manshav, are still building out region by region. If your buyer profile is a private hospital chain in Germany or a Japanese-linked aid program, brand pedigree still counts for something real.
In short: Manshav and other Indian disposable syringes manufacturers meet the same ISO 7886-1 and ISO 7864 standards as B. Braun and Terumo, but price 60-70% lower landed with 3-5 week lead times to African and Gulf ports versus 6-10 weeks through multinational distributor chains — a real edge for volume tenders on fixed budgets.
Ready to compare landed cost on your next tender or hospital order?
Is Manshav's syringe quality actually comparable to B. Braun or Terumo?
On the core standards that matter for clinical use — ISO 7886-1 sterility and material safety, ISO 7864 needle sharpness — yes, tested batches fall within the same tolerance bands. The difference buyers notice is in brand-service infrastructure, not the syringe itself.
Why is Manshav's FOB price so much lower than the multinational brands?
Lower manufacturing overhead in India, shorter distribution chains for factory-direct export, and pricing closer to production cost rather than brand-premium markup. Freight to most African and GCC ports is also faster and cheaper than routing through European or Japanese regional hubs.
Can Manshav supply syringes for a WHO-prequalified or donor-funded tender?
Yes — Manshav's plants are WHO-GMP compliant and ISO 13485 certified, and can provide full technical dossiers, CoAs, and registration support documents most donor-funded tenders require. Confirm specific donor-brand restrictions with the tender authority before bidding, since some programs mandate named suppliers.
Manshav Impex
Manshav Impex is a global exporter of medical devices, surgical consumables and healthcare solutions, serving importers, distributors, hospitals and governments in 48+ countries.